Humana Inc. (NYSE:HUM) Receives $296.39 Average Price Target from Brokerages

Shares of Humana Inc. (NYSE:HUM) have been given an average recommendation of “Hold” by the twenty-eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, nine have assigned a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $325.8696.

HUM has been the subject of a number of research analyst reports. Royal Bank Of Canada lifted their target price on shares of Humana from $246.00 to $415.00 and gave the stock a “sector perform” rating in a research report on Thursday, July 9th. Raymond James Financial set a $300.00 price target on Humana in a research note on Tuesday, July 7th. Robert W. Baird cut their price objective on Humana from $264.00 to $205.00 and set a “neutral” rating for the company in a report on Wednesday, April 15th. Bank of America upped their price objective on Humana from $340.00 to $380.00 and gave the company a “neutral” rating in a research report on Wednesday, June 24th. Finally, TD Cowen raised their target price on Humana from $211.00 to $350.00 and gave the stock a “hold” rating in a research report on Tuesday.

Hedge Funds Weigh In On Humana

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Montag A & Associates Inc. raised its position in Humana by 1,880.0% in the fourth quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after acquiring an additional 94 shares during the period. CoreCap Advisors LLC grew its position in shares of Humana by 54.4% during the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock valued at $27,000 after acquiring an additional 37 shares during the period. Fideuram Asset Management Ireland dac bought a new stake in shares of Humana during the 4th quarter valued at $27,000. Reflection Asset Management purchased a new stake in shares of Humana in the 4th quarter worth $29,000. Finally, Rosenberg Matthew Hamilton raised its holdings in Humana by 136.0% in the 4th quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock worth $30,000 after purchasing an additional 68 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Trending Headlines about Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Zacks Research upgraded Humana (HUM) to strong-buy, signaling improved analyst confidence in the insurer’s outlook. Zacks upgrade report
• Positive Sentiment: Zacks Research raised earnings estimates across several periods, including FY2026 EPS to $9.04 and FY2027 EPS to $13.30, reinforcing the view that Humana’s earnings may improve materially over the next few years.
• Positive Sentiment: Truist Financial increased its price target on Humana to $415, close to the stock’s recent trading range, which can help validate the current rally. Truist price target raise
• Neutral Sentiment: Investors are also weighing commentary about whether Humana is already fully valued after its recent run, which may limit upside unless upcoming results confirm the improved earnings outlook. Yahoo Finance valuation article
• Neutral Sentiment: One article argues that Humana’s Q2 earnings need to catch up with the stock’s performance, meaning the market may be awaiting confirmation from the upcoming report before pushing the shares much higher. Seeking Alpha article
• Negative Sentiment: News that Humana’s agreement with Wexner Medical Center is set to end in October, and another report that its insurance network is terminating an agreement with Ohio State, could raise concerns about network disruption or member retention. Wexner Medical Center agreement article

Humana Price Performance

HUM opened at $406.98 on Thursday. The company’s 50-day simple moving average is $348.73 and its two-hundred day simple moving average is $258.30. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.77 and a current ratio of 1.77. The stock has a market capitalization of $48.86 billion, a P/E ratio of 43.53, a P/E/G ratio of 2.32 and a beta of 0.71. Humana has a 52-week low of $163.11 and a 52-week high of $415.00.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $10.31 EPS for the quarter, topping analysts’ consensus estimates of $9.97 by $0.34. The firm had revenue of $39.65 billion during the quarter, compared to analyst estimates of $39.37 billion. Humana had a net margin of 0.82% and a return on equity of 10.45%. The business’s revenue for the quarter was up 23.5% on a year-over-year basis. During the same period in the previous year, the business posted $11.58 earnings per share. Humana has set its FY 2026 guidance at 9.000- EPS. As a group, analysts predict that Humana will post 9.04 EPS for the current year.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.